ES2530743T3 - Método in vitro y kit para el pronóstico o predicción de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor TNFalfa - Google Patents

Método in vitro y kit para el pronóstico o predicción de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor TNFalfa Download PDF

Info

Publication number
ES2530743T3
ES2530743T3 ES09815707T ES09815707T ES2530743T3 ES 2530743 T3 ES2530743 T3 ES 2530743T3 ES 09815707 T ES09815707 T ES 09815707T ES 09815707 T ES09815707 T ES 09815707T ES 2530743 T3 ES2530743 T3 ES 2530743T3
Authority
ES
Spain
Prior art keywords
patients
treatment
prognosis
prediction
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09815707T
Other languages
English (en)
Inventor
Cano Antonio Julia
Barril Sara Marsal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacio Institut de Recerca Hospital Universitari Vall dHebron
Original Assignee
Fundacio Institut de Recerca Hospital Universitari Vall dHebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Institut de Recerca Hospital Universitari Vall dHebron filed Critical Fundacio Institut de Recerca Hospital Universitari Vall dHebron
Application granted granted Critical
Publication of ES2530743T3 publication Critical patent/ES2530743T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Método in vitro y kit para el pronóstico o predicción de la respuesta al tratamiento con agentes bloqueantes del factor TNFa por parte de pacientes con artritis reumatoide, que comprende la determinación en una muestra de sangre de dichos pacientes del nivel de expresión de al menos uno de los ocho genes seleccionado del grupo: HLA-DRB3, EAT2, GNLY, CAMP, SLC2A3, IL2RB, MXD4 y TLR5 o decombinaciones de los mismos y la comparación de dicho nivel de expresión con respecto a los valores de expresión obtenidos de pacientes respondedores al tratamiento y no respondedores al mismo.
ES09815707T 2008-09-24 2009-09-18 Método in vitro y kit para el pronóstico o predicción de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor TNFalfa Active ES2530743T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200802713A ES2335381B1 (es) 2008-09-24 2008-09-24 Metodo in vitro y kit para el pronostico o prediccion de la respuestapor parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor tnfalfa.
PCT/ES2009/070388 WO2010034864A1 (es) 2008-09-24 2009-09-18 MÉTODO IN VITRO Y KIT PARA EL PRONÓSTICO O PREDICCIÓN DE LA RESPUESTA POR PARTE DE PACIENTES CON ARTRITIS REUMATOIDE AL TRATAMIENTO CON AGENTES BLOQUEANTES DEL FACTOR TNFalfa

Publications (1)

Publication Number Publication Date
ES2530743T3 true ES2530743T3 (es) 2015-03-05

Family

ID=41808917

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200802713A Expired - Fee Related ES2335381B1 (es) 2008-09-24 2008-09-24 Metodo in vitro y kit para el pronostico o prediccion de la respuestapor parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor tnfalfa.
ES09815707T Active ES2530743T3 (es) 2008-09-24 2009-09-18 Método in vitro y kit para el pronóstico o predicción de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor TNFalfa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES200802713A Expired - Fee Related ES2335381B1 (es) 2008-09-24 2008-09-24 Metodo in vitro y kit para el pronostico o prediccion de la respuestapor parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor tnfalfa.

Country Status (6)

Country Link
US (1) US9441274B2 (es)
EP (1) EP2333110B1 (es)
CA (1) CA2738207A1 (es)
DK (1) DK2333110T3 (es)
ES (2) ES2335381B1 (es)
WO (1) WO2010034864A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2265643B1 (en) 2008-03-13 2016-10-19 Biotest AG Dosing regimen for treating psoriasis and rheumatoid arthritis
CN102027016A (zh) 2008-03-13 2011-04-20 生物测试股份公司 一种治疗疾病的试剂
RU2540018C2 (ru) 2008-03-13 2015-01-27 Биотест Аг Средство для лечения заболевания
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
EP2550367B1 (en) * 2010-03-24 2017-03-22 TC LAND Expression Genes and genes combinations predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (cytd)
WO2012101183A2 (en) * 2011-01-25 2012-08-02 Tc Land Expression Genes and genes combinations based on gene mknk1 predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (cytd) or anti-inflammatory biological drugs
EP2813850A1 (en) * 2013-06-10 2014-12-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting rheumatoid arthritis treatment response
EP3194611A1 (en) * 2014-08-01 2017-07-26 Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca Method to predict the lack of response to anti-tnf alpha therapies
WO2019060330A1 (en) 2017-09-19 2019-03-28 Momenta Pharmaceuticals, Inc. METHODS OF PREDICTION OF RESPONSE TO TREATMENT

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6893828B2 (en) * 2001-09-06 2005-05-17 Decode Genetics Ehf. Methods for producing ex vivo models for inflammatory disease and uses thereof
WO2007038501A2 (en) * 2005-09-27 2007-04-05 The Feinstein Institute For Medical Research Rheumatoid arthritis markers
EP1857559A1 (en) * 2006-05-16 2007-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for predicting responsiveness to TNF alpha blocking agents
EP2132343B1 (en) * 2007-03-01 2012-08-29 Université Catholique de Louvain Method for the determination and the classification of rheumatic conditions
WO2008132176A2 (en) * 2007-04-27 2008-11-06 Universite Catholique De Louvain Method for evaluating the response of an individual to tnf blocking therapy
WO2008150491A2 (en) * 2007-05-31 2008-12-11 Abbott Laboratories BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS
EP2550367B1 (en) * 2010-03-24 2017-03-22 TC LAND Expression Genes and genes combinations predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (cytd)

Also Published As

Publication number Publication date
DK2333110T3 (en) 2015-02-23
ES2335381A1 (es) 2010-03-25
EP2333110A9 (en) 2011-11-02
CA2738207A1 (en) 2010-04-01
WO2010034864A1 (es) 2010-04-01
ES2335381B1 (es) 2011-02-28
EP2333110B1 (en) 2014-11-19
US20110263449A1 (en) 2011-10-27
US9441274B2 (en) 2016-09-13
EP2333110A4 (en) 2012-02-08
EP2333110A1 (en) 2011-06-15

Similar Documents

Publication Publication Date Title
ES2530743T3 (es) Método in vitro y kit para el pronóstico o predicción de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor TNFalfa
AR122771A2 (es) Anticuerpos para el tratamiento del cáncer, conjugado, composición farmacéutica, ácido nucleico y célula huésped
AR084373A1 (es) Composiciones y metodos para la eliminacion de biopeliculas
MX2013014153A (es) Biomarcadores paa terapia de inhibidor de hedgehog.
CR20110066A (es) Anticuerpos monoclonales contra el factor tisular inhibidor de la via
EA201600085A1 (ru) Набор для обнаружения соевого события syht0h2
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
ES2527592T3 (es) Métodos basados en microARN para el diagnóstico del cáncer de colon
EA201391587A1 (ru) Комбинированная терапия на основе hsp90
EA201100300A1 (ru) Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента
EA201300583A1 (ru) Вазопротективное и кардиопротективное противодиабетическое лечение
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
CL2008002153A1 (es) Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
EP2061907A4 (en) Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181
EA201590247A1 (ru) Антитела к siglec-15
IN2012DN02485A (es)
EA200971079A1 (ru) ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ
MX382403B (es) Métodos para predecir el riesgo de desarrollar hipertensión.
EA200970891A1 (ru) Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы
BR112014025768A2 (pt) métodos de tratamento de espondilite anquilosante usando antagonistas de il-17
PE20160192A1 (es) Composiciones y metodo para tratar condiciones asociadas con el complemento
UY35075A (es) Biomarcadores predictivos de la respuesta clínica al acetato de glatirámero
MX2025004103A (es) Metodos de identificacion de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa
BR112021015222A2 (pt) Métodos, sistemas e kits para tratamento de doença inflamatória de alvejamento de il18r1